$TELA
TELA Bio Inc

2023 Q3 Form 10-Q Financial Statement

#000155837023014494 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $15.05M $14.49M
YoY Change 34.89% 39.29%
Cost Of Revenue $4.660M $4.293M
YoY Change 21.35% 11.33%
Gross Profit $10.39M $10.20M
YoY Change 41.95% 55.74%
Gross Profit Margin 69.02% 70.38%
Selling, General & Admin $18.20M $18.05M
YoY Change 23.79% 22.91%
% of Gross Profit 175.2% 176.93%
Research & Development $2.368M $2.514M
YoY Change 12.65% 19.6%
% of Gross Profit 22.79% 24.64%
Depreciation & Amortization $220.0K $214.0K
YoY Change 7.32% -65.54%
% of Gross Profit 2.12% 2.1%
Operating Expenses $20.57M $20.56M
YoY Change 22.4% 22.49%
Operating Profit -$10.18M -$10.36M
YoY Change 7.32% 1.22%
Interest Expense $1.334M $1.298M
YoY Change 29.26% 38.97%
% of Operating Profit
Other Income/Expense, Net -$776.0K -$428.0K
YoY Change -36.76% -82.91%
Pretax Income -$10.96M -$10.79M
YoY Change 2.3% -15.31%
Income Tax
% Of Pretax Income
Net Earnings -$10.96M -$10.79M
YoY Change 2.27% -15.31%
Net Earnings / Revenue -72.79% -74.44%
Basic Earnings Per Share -$0.45 -$0.46
Diluted Earnings Per Share -$0.45 -$0.46
COMMON SHARES
Basic Shares Outstanding 24.49M 24.45M
Diluted Shares Outstanding 24.48M 23.24M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.20M $65.27M
YoY Change 7.33% 135.4%
Cash & Equivalents $58.20M $65.27M
Short-Term Investments
Other Short-Term Assets $1.660M $1.910M
YoY Change -12.77% -17.39%
Inventory $14.32M $14.10M
Prepaid Expenses
Receivables $8.070M $7.894M
Other Receivables $0.00 $0.00
Total Short-Term Assets $82.25M $89.17M
YoY Change 11.22% 95.4%
LONG-TERM ASSETS
Property, Plant & Equipment $1.749M $1.764M
YoY Change 0.06% 3.4%
Goodwill
YoY Change
Intangibles $2.214M $2.309M
YoY Change -14.65% -14.13%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $5.065M $5.218M
YoY Change -9.68% -8.44%
TOTAL ASSETS
Total Short-Term Assets $82.25M $89.17M
Total Long-Term Assets $5.065M $5.218M
Total Assets $87.32M $94.39M
YoY Change 9.75% 83.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.091M $2.250M
YoY Change -36.35% 0.18%
Accrued Expenses $12.24M $10.80M
YoY Change 18.2% 11.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.33M $13.05M
YoY Change 0.79% 9.38%
LONG-TERM LIABILITIES
Long-Term Debt $40.36M $40.21M
YoY Change 1.5% 1.5%
Other Long-Term Liabilities $1.068M $1.124M
YoY Change -16.69% -15.62%
Total Long-Term Liabilities $41.43M $41.34M
YoY Change 0.93% 0.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.33M $13.05M
Total Long-Term Liabilities $41.43M $41.34M
Total Liabilities $56.77M $54.38M
YoY Change 0.89% 2.85%
SHAREHOLDERS EQUITY
Retained Earnings -$308.0M -$297.0M
YoY Change 16.58% 17.16%
Common Stock $24.00K $24.00K
YoY Change 26.32% 60.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.55M $40.01M
YoY Change
Total Liabilities & Shareholders Equity $87.32M $94.39M
YoY Change 9.75% 83.87%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$10.96M -$10.79M
YoY Change 2.27% -15.31%
Depreciation, Depletion And Amortization $220.0K $214.0K
YoY Change 7.32% -65.54%
Cash From Operating Activities -$6.970M -$11.26M
YoY Change -8.88% -3.61%
INVESTING ACTIVITIES
Capital Expenditures $140.0K $157.0K
YoY Change -148.28% -178.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$140.0K -$157.0K
YoY Change -51.72% -21.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 80.00K 46.41M
YoY Change -99.77% 598.09%
NET CHANGE
Cash From Operating Activities -6.970M -11.26M
Cash From Investing Activities -140.0K -157.0K
Cash From Financing Activities 80.00K 46.41M
Net Change In Cash -7.030M 34.99M
YoY Change -126.4% -767.96%
FREE CASH FLOW
Cash From Operating Activities -$6.970M -$11.26M
Capital Expenditures $140.0K $157.0K
Free Cash Flow -$7.110M -$11.42M
YoY Change -3.38% -0.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24475504
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19165027
dei Entity Central Index Key
EntityCentralIndexKey
0001561921
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39130
dei Entity Registrant Name
EntityRegistrantName
TELA Bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5320061
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Great Valley Parkway, Suite 24
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
320-2930
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
TELA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24487451
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65266000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42019000
CY2023Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
7894000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6621000
CY2023Q2 us-gaap Inventory Net
InventoryNet
14098000
CY2022Q4 us-gaap Inventory Net
InventoryNet
11792000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1910000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2015000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
89168000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
62447000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1764000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1682000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2309000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2499000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1145000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1227000
CY2023Q2 us-gaap Assets
Assets
94386000
CY2022Q4 us-gaap Assets
Assets
67855000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2250000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1534000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10795000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10869000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13045000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12403000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40212000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39916000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1124000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1231000
CY2023Q2 us-gaap Liabilities
Liabilities
54381000
CY2022Q4 us-gaap Liabilities
Liabilities
53550000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21616000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20081000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24475504
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19165027
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
24000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
336939000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
288361000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
84000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297042000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274225000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40005000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14305000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94386000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67855000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14494000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10406000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26403000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18637000
CY2023Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
4198000
CY2022Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
3318000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
8114000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6474000
CY2023Q2 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
95000
CY2022Q2 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
538000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
190000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
614000
CY2023Q2 us-gaap Gross Profit
GrossProfit
10201000
CY2022Q2 us-gaap Gross Profit
GrossProfit
6550000
us-gaap Gross Profit
GrossProfit
18099000
us-gaap Gross Profit
GrossProfit
11549000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14577000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11055000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28043000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20433000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3472000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3630000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7106000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7088000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2514000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2102000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4566000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4109000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
20563000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
16787000
us-gaap Operating Expenses
OperatingExpenses
39715000
us-gaap Operating Expenses
OperatingExpenses
31630000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10362000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10237000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1298000
CY2022Q2 us-gaap Interest Expense
InterestExpense
934000
us-gaap Interest Expense
InterestExpense
2544000
us-gaap Interest Expense
InterestExpense
1845000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1228000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1228000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
870000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-342000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1343000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-449000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-428000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2504000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1201000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3522000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10790000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12741000
us-gaap Net Income Loss
NetIncomeLoss
-22817000
us-gaap Net Income Loss
NetIncomeLoss
-23603000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.62
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23239262
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23239262
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14557453
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14557453
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21223639
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21223639
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14548210
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14548210
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10790000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12741000
us-gaap Net Income Loss
NetIncomeLoss
-22817000
us-gaap Net Income Loss
NetIncomeLoss
-23603000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-36000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
134000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-66000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
181000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10826000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12607000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22883000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23422000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3141000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
56000
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-36000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1294000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46341000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10790000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40005000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14305000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
280000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-66000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2422000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46341000
us-gaap Net Income Loss
NetIncomeLoss
-22817000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40005000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
10038000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
134000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1022000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12741000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1542000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20098000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
153000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
181000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1923000
us-gaap Net Income Loss
NetIncomeLoss
-23603000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1542000
us-gaap Profit Loss
ProfitLoss
-22817000
us-gaap Profit Loss
ProfitLoss
-23603000
us-gaap Depreciation
Depreciation
239000
us-gaap Depreciation
Depreciation
161000
us-gaap Paid In Kind Interest
PaidInKindInterest
296000
us-gaap Paid In Kind Interest
PaidInKindInterest
359000
tela Noncash Loss On Extinguishment Of Debt
NoncashLossOnExtinguishmentOfDebt
1228000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
190000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
614000
tela Net Changes In Operating Lease Right Of Use Assets And Liabilities
NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
22000
tela Net Changes In Operating Lease Right Of Use Assets And Liabilities
NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
17000
us-gaap Inventory Write Down
InventoryWriteDown
704000
us-gaap Inventory Write Down
InventoryWriteDown
1193000
us-gaap Share Based Compensation
ShareBasedCompensation
2422000
us-gaap Share Based Compensation
ShareBasedCompensation
1923000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1219000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1115000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2936000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3987000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-107000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-920000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
651000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-411000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-104000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
216000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
349000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-403000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22838000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22116000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
272000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
536000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-272000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-536000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46354000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
40000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
30000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
3357000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
280000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
153000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46174000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6502000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-56000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23247000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16206000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42019000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43931000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65266000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27725000
us-gaap Interest Paid Net
InterestPaidNet
2248000
us-gaap Interest Paid Net
InterestPaidNet
1486000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
49000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
146000
tela Offering Costs In Accounts Payable And Accrued Expense And Other Current Liabilities
OfferingCostsInAccountsPayableAndAccruedExpenseAndOtherCurrentLiabilities
13000
tela Offering Costs In Accounts Payable And Accrued Expense And Other Current Liabilities
OfferingCostsInAccountsPayableAndAccruedExpenseAndOtherCurrentLiabilities
103000
tela Accrued Milestone Payment Current
AccruedMilestonePaymentCurrent
1000000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1376000
tela Tenant Improvements And Deferred Rent Exchanged For Operating Lease Liabilities
TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities
380000
tela Operating Lease Obligation Assumed
OperatingLeaseObligationAssumed
-1756000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company’s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.</p>
tela Incremental Costs Of Obtaining Contract
IncrementalCostsOfObtainingContract
0
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14494000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10406000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26403000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18637000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3088399
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3088399
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2357760
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2357760
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
181000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
366000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
375000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
383000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
392000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
164000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1861000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
394000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1467000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1100000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6235000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6420000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2220000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2563000
CY2023Q2 tela Accrued Expenses Amount Due To Contract Manufacturer
AccruedExpensesAmountDueToContractManufacturer
1629000
CY2022Q4 tela Accrued Expenses Amount Due To Contract Manufacturer
AccruedExpensesAmountDueToContractManufacturer
1263000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
343000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
340000
CY2023Q2 tela Research And Development Expenses Payable Current
ResearchAndDevelopmentExpensesPayableCurrent
115000
CY2022Q4 tela Research And Development Expenses Payable Current
ResearchAndDevelopmentExpensesPayableCurrent
137000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
253000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10795000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10869000
CY2023Q2 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
2000000
CY2022Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
2000000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1788000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2084000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
40212000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
39916000
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
88556
CY2023Q2 tela Equity Incentive Plans Number
EquityIncentivePlansNumber
2
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1294000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1022000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2422000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1923000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2071848
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
212960
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.50
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
19429
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
46547
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.03
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2218832
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M19D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2170777
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y11M4D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1456572
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y29D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
35000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.743
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0399
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M24D

Files In Submission

Name View Source Status
0001558370-23-014494-index-headers.html Edgar Link pending
0001558370-23-014494-index.html Edgar Link pending
0001558370-23-014494.txt Edgar Link pending
0001558370-23-014494-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tela-20230630.xsd Edgar Link pending
tela-20230630x10q.htm Edgar Link pending
tela-20230630xex10d1.htm Edgar Link pending
tela-20230630xex31d1.htm Edgar Link pending
tela-20230630xex31d2.htm Edgar Link pending
tela-20230630xex32d1.htm Edgar Link pending
tela-20230630xex32d2.htm Edgar Link pending
tela-20230630_def.xml Edgar Link unprocessable
tela-20230630_lab.xml Edgar Link unprocessable
tela-20230630_pre.xml Edgar Link unprocessable
tela-20230630x10q_htm.xml Edgar Link completed
tela-20230630_cal.xml Edgar Link unprocessable